Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MAVERICK NEUTRAL LEVERED FUND, LTD. et al v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. et al
Case Number:
3:20-cv-02190
Court:
Nature of Suit:
Judge:
Firms
- Debevoise & Plimpton
- Kirby McInerney
- McCarter & English
- McDermott Will & Schulte
- McElroy Deutsch
- Mintz Levin
- Winston & Strawn
Companies
Sectors & Industries:
-
January 27, 2021
Special Master Urges Toss Of Opt-Out Valeant Investor Suit
A small group of investors in the company formerly known as Valeant Pharmaceuticals International Inc. waited too long to bring securities fraud claims against the company, a former federal judge in New Jersey said Tuesday.
-
June 01, 2020
Bausch Says Investors' Price-Gouging Claims Came Too Late
Bausch Health Cos. Inc. and its brass on Friday sought to shed a securities fraud lawsuit that alleges the company engaged in a price-gouging scheme that cost investors billions, telling a New Jersey federal judge that investors' claims came too late.
-
February 28, 2020
Maverick Funds Sue Bausch Claiming Valeant Price-Gouging
Bausch Health Cos. Inc. was hit with a securities fraud suit in New Jersey federal court Friday from companies managed by hedge fund Maverick Capital alleging that the business, then known as Valeant Pharmaceuticals International Inc., engaged in a price-gouging scheme that cost investors billions.